G42 joins forces with Israeli Rafael and IAI to defeat Covid-19
The companies will explore joint research and development programs to develop groundbreaking solutions against the coronavirus.
Abu Dhabi – July 2, 2020: Group 42 (G42), a leading technology company based in Abu Dhabi, announced today it has signed two distinct Memorandums of Understanding with Rafael Advanced Defense Systems (Rafael) and Israel Aerospace Industries (IAI), two leading Israeli technology companies, to explore collaborations in the research and development of effective solutions to combat SARS-CoV-2, the virus that causes Covid-19 disease.
Executives from each company took part in a signing ceremony held via video conference between the UAE and Israel. During the event, they discussed ways of leveraging respective expertise and technologies to develop cutting-edge solutions and medical initiatives that could benefit, not only the population of the two countries, but humanity as a whole.
Mr. Peng Xiao, CEO of Group 42, said: “At G42 we have always embraced international cooperation as a way to create better and more effective technologies for the public good. The UAE leadership has long advocated for a global collaborative effort to defeat the Covid-19 pandemic, and we are privileged to follow the lead and share our resources and expertise with Rafael and IAI for such a significant cause.”
This joint initiative brings together some of the most active actors in the Covid-19 response in the region and aims to combine their respective knowledge, personnel, technology and resources to conceptualize, develop and optimize breakthrough solutions that will help the world fight Covid-19 and safeguard public health.
G42 is at the forefront in the battle against COVID-19 since the outbreak. Thanks to its expertise in AI-driven genomics, the company has recently announced the development, in partnership with UK’s Oxford Nanopore Technologies, of an end-to-end detection solution with ultra-high throughput to screen in mass and on demand, in order to support the re-opening of global economies.
In the UAE, G42 is also operating, the world’s first phase III clinical trial of a COVID-19 inactivated vaccine, under the supervision of the Department of Health of Abu Dhabi.
